- Home
- IMNN vs APLM Comparison
IMNN vs APLM Comparison
Compare IMNN & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- APLM
- Stock Information
- Founded
- IMNN 1982
- APLM 2016
- Country
- IMNN United States
- APLM United States
- Employees
- IMNN N/A
- APLM N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- APLM Blank Checks
- Sector
- IMNN Health Care
- APLM Finance
- Exchange
- IMNN Nasdaq
- APLM Nasdaq
- Market Cap
- IMNN 12.1M
- APLM 6.9M
- IPO Year
- IMNN 1985
- APLM N/A
- Fundamental
- Price
- IMNN $0.60
- APLM $5.33
- Analyst Decision
- IMNN Buy
- APLM
- Analyst Count
- IMNN 2
- APLM 0
- Target Price
- IMNN $14.00
- APLM N/A
- AVG Volume (30 Days)
- IMNN 1.3M
- APLM 26.7K
- Earning Date
- IMNN 08-13-2025
- APLM 08-13-2025
- Dividend Yield
- IMNN N/A
- APLM N/A
- EPS Growth
- IMNN N/A
- APLM N/A
- EPS
- IMNN N/A
- APLM N/A
- Revenue
- IMNN N/A
- APLM $198,000.00
- Revenue This Year
- IMNN N/A
- APLM $415.15
- Revenue Next Year
- IMNN N/A
- APLM N/A
- P/E Ratio
- IMNN N/A
- APLM N/A
- Revenue Growth
- IMNN N/A
- APLM N/A
- 52 Week Low
- IMNN $0.37
- APLM $4.47
- 52 Week High
- IMNN $3.65
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- IMNN 35.40
- APLM 44.49
- Support Level
- IMNN $0.70
- APLM $5.33
- Resistance Level
- IMNN $0.86
- APLM $6.56
- Average True Range (ATR)
- IMNN 0.07
- APLM 0.54
- MACD
- IMNN -0.03
- APLM -0.05
- Stochastic Oscillator
- IMNN 0.05
- APLM 33.11
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.